BRAF-MEK Inhibitor Combo Extends Survival in BRAF-Mutant Melanoma

The combination of encorafenib and binimetinib resulted in longer overall survival compared with vemurafenib in patients with BRAF V600 –mutant melanoma.

Source: CancerNetwork - October 4, 2018 Category: Cancer & Oncology Authors: Dave Levitan Source Type: news